Trial Profile
Ireland TYSABRI (Natalizumab) Observational Program (iTOP)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational
- Acronyms iTOP
- Sponsors Biogen
- 15 Oct 2021 Results (As of December 2017) presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 03 May 2018 Status changed from active, no longer recruiting to completed.
- 10 Jul 2015 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov record.